Clinical Trial Update: MGD019 DART® Protein in Unresectable/Metastatic Cancer [Phase 1]

View source ↗

Summary

MGD019, a DART protein from MacroGenics, is being studied in a Phase 1 trial for unresectable/metastatic cancers, including non-small cell lung cancer, metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Prostate Cancer

Drugs mentioned

• MGD019 DART (MGD019)

Snippet

Sponsor: MacroGenics | Conditions: Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic | Phase 1 | Status: COMPLETED